🚀 VC round data is live in beta, check it out!
Dogwood Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dogwood Therapeutics and similar public comparables like Nanexa, Adicet Bio, Oncocross, ImmuCell and more.
Dogwood Therapeutics Overview
About Dogwood Therapeutics
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Founded
2020
HQ
Employees
12
Website
Sectors
Financials (LTM)
EV
$60M
Dogwood Therapeutics Financials
Dogwood Therapeutics reported last 12-month revenue of —.
In the same LTM period, Dogwood Therapeutics generated had net loss of ($32M).
Revenue (LTM)
Dogwood Therapeutics P&L
In the most recent fiscal year, Dogwood Therapeutics reported revenue of — and EBITDA of ($28M).
Dogwood Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($28M) | XXX | XXX | XXX |
| Net Profit | ($32M) | XXX | ($34M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dogwood Therapeutics Stock Performance
Dogwood Therapeutics has current market cap of $66M, and enterprise value of $60M.
Market Cap Evolution
Dogwood Therapeutics' stock price is $1.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60M | $66M | 3.1% | XXX | XXX | XXX | $-1.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDogwood Therapeutics Valuation Multiples
Dogwood Therapeutics trades at (2.1x) EV/EBITDA.
Dogwood Therapeutics Financial Valuation Multiples
As of April 11, 2026, Dogwood Therapeutics has market cap of $66M and EV of $60M.
Equity research analysts estimate Dogwood Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dogwood Therapeutics has a P/E ratio of (2.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV (current) | $60M | XXX | $60M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.1x) | XXX | XXX | XXX |
| P/E | (2.1x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dogwood Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dogwood Therapeutics Margins & Growth Rates
Dogwood Therapeutics' revenue in the last fiscal year grew by —.
Dogwood Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.3M for the same period.
Dogwood Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 128% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dogwood Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanexa | XXX | XXX | XXX | XXX | XXX | XXX |
| Adicet Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| ImmuCell | XXX | XXX | XXX | XXX | XXX | XXX |
| Entera Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dogwood Therapeutics M&A Activity
Dogwood Therapeutics acquired XXX companies to date.
Last acquisition by Dogwood Therapeutics was on XXXXXXXX, XXXXX. Dogwood Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dogwood Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDogwood Therapeutics Investment Activity
Dogwood Therapeutics invested in XXX companies to date.
Dogwood Therapeutics made its latest investment on XXXXXXXX, XXXXX. Dogwood Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dogwood Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dogwood Therapeutics
| When was Dogwood Therapeutics founded? | Dogwood Therapeutics was founded in 2020. |
| Where is Dogwood Therapeutics headquartered? | Dogwood Therapeutics is headquartered in United States. |
| How many employees does Dogwood Therapeutics have? | As of today, Dogwood Therapeutics has over 12 employees. |
| Who is the CEO of Dogwood Therapeutics? | Dogwood Therapeutics' CEO is Gregory Duncan. |
| Is Dogwood Therapeutics publicly listed? | Yes, Dogwood Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Dogwood Therapeutics? | Dogwood Therapeutics trades under DWTX ticker. |
| When did Dogwood Therapeutics go public? | Dogwood Therapeutics went public in 2020. |
| Who are competitors of Dogwood Therapeutics? | Dogwood Therapeutics main competitors are Nanexa, Adicet Bio, Oncocross, ImmuCell. |
| What is the current market cap of Dogwood Therapeutics? | Dogwood Therapeutics' current market cap is $66M. |
| Is Dogwood Therapeutics profitable? | No, Dogwood Therapeutics is not profitable. |
| What is the current net income of Dogwood Therapeutics? | Dogwood Therapeutics' last 12 months net income is ($32M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.